High-Throughput Determination of Infectious Virus Titers by Kinetic Measurement of Infection-Induced Changes in Cell Morphology

Author:

Hotter Dominik1,Kunzelmann Marco2ORCID,Kiefer Franziska1,Leukhardt Chiara1,Fackler Carolin1,Jäger Stefan3,Solzin Johannes1ORCID

Affiliation:

1. Boehringer Ingelheim Pharma GmbH & Co. KG, Viral Therapeutics Center, 88397 Biberach an der Riss, Germany

2. Boehringer Ingelheim Pharma GmbH & Co. KG, Development Biologicals, 88397 Biberach an der Riss, Germany

3. Boehringer Ingelheim Pharma GmbH & Co. KG, Central Nervous System Diseases Research, 88397 Biberach an der Riss, Germany

Abstract

Infectivity assays are the key analytical technology for the development and manufacturing of virus-based therapeutics. Here, we introduce a novel assay format that utilizes label-free bright-field images to determine the kinetics of infection-dependent changes in cell morphology. In particular, cell rounding is directly proportional to the amount of infectious virus applied, enabling rapid determination of viral titers in relation to a standard curve. Our kinetic infectious virus titer (KIT) assay is stability-indicating and, due to its sensitive readout method, provides results within 24 h post-infection. Compared to traditional infectivity assays, which depend on a single readout of an infection endpoint, cumulated analysis of kinetic data by a fit model results in precise results (CV < 20%) based on only three wells per sample. This approach allows for a high throughput with ~400 samples processed by a single operator per week. We demonstrate the applicability of the KIT assay for the genetically engineered oncolytic VSV-GP, Newcastle disease virus (NDV), and parapoxvirus ovis (ORFV), but it can potentially be extended to a wide range of viruses that induce morphological changes upon infection. The versatility of this assay, combined with its independence from specific instruments or software, makes it a promising solution to overcome the analytical bottleneck in infectivity assays within the pharmaceutical industry and as a routine method in academic research.

Publisher

MDPI AG

Reference36 articles.

1. Zhao, Z., Anselmo, A.C., and Mitragotri, S. (2021). Viral Vector-based Gene Therapies in the Clinic. Bioeng. Transl. Med., 7.

2. A High-Throughput Label-Free Nanoparticle Analyser;Fraikin;Nat. Nanotechnol.,2011

3. Businger, R., Hochdorfer, D., Hotter, D., and Solzin, J. (2023). Bioprocess and Analytics Development for Virus-Based Advanced Therapeutics and Medicinal Products (ATMPs), Springer.

4. Beitrag Zur Kollektiven Behandlung Pharmakologischer Reihenversuche;Naunyn-Schmiedebergs Arch. für Exp. Pathol. Pharmakol.,1931

5. The Method of ‘Right and Wrong Cases’ (‘Constant Stimuli’) without Gauss’S Formulae;SPEARMAN;Br. J. Psychol.,1908

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3